DTX3

Across TCGA pan-cancer cohorts, DTX3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DTX3 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DTX3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DTX3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LUAD, and LIHC are the cancer types where DTX3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.250	0.692	.009	18	view →
LUAD	OS	Median	II,III,IV	0.245	0.749	.019	12	view →
LIHC	DFS	Median	All	0.130	0.546	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.630	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DTX3–OV (OS)

Open the OV breakdown →